NewzVille Desk
An Industry Interaction on the theme “Scaling up Pharma Exports” was held under the Chintan Shivir series being taken forward. The interaction reflected the Government’s priority of expanding India’s export footprint through closer coordination with industry and regulators.
Stakeholders deliberated on scaling exports further, with the industry targeting double-digit expansion in 2026–27. The ₹10,000 crore Biopharma SHAKTI initiative was highlighted as a key step to strengthen domestic capabilities and reduce import dependence in biologics, paving the way for sustained export growth.
India’s pharmaceutical export performance continues to show steady growth. Pharmaceutical exports stood at USD 30.47 billion in FY 2024–25, registering a growth of 9.4 per cent over the previous year.
The sector, currently valued at around USD 60 billion, is projected to reach USD 130 billion by 2030.
India ranks third globally by volume, with medicines exported to over 200 markets, and more than 60 per cent of exports destined for stringent regulatory markets.
The United States accounts for 34 per cent and Europe for 19 per cent of India’s pharmaceutical exports.
The interaction underlined the Government’s focus on enabling conditions for sustained export acceleration, with industry indicating readiness to target double-digit growth in 2026–27.
